GenSpera, Inc.

(OTCBB:GNSZ) is a biotechnology company

focused on the development of cancer therapeutics based on a
new technology platform. Its lead drug candidate has impressive
pre-clinical results and is currently undergoing Phase I clinical
evaluation.

GenSpera, Inc.
2511 N Loop 1604 W, Suite 204
San Antonio, Texas 78258
Precise targeting of a potent, unique drug directly to tumors
www.genspera.com
Breakthrough technology
Company Contact • Based on over $15M of funding and 15 years of research at Johns
Craig A. Dionne, PhD Hopkins Medical Center and other renowned research centers
President and CEO • Lead drug is a major breakthrough that could lead to complete tumor
(210) 479-8112 regression
cdionne@genspera.com • Destroys tumor blood vessels rather than just blocking new growth
• New mechanism of action unlike existing vascular disrupting
Investor Relations
Steve Chizzik
agents, anti-angiogenics or traditional chemotherapeutics
The Verrazano Group • Unique cytotoxin kills cancer cells independent of cell division – useful
(908) 688-9111 for cancer stem cells and slow (i.e., prostate) and fast growing cancers
steve@theverrazanogroup.com
Enormous market
• New cancer drugs are treating cancers by blocking the growth of new
Capital Markets Summary blood vessels to tumors
• Even though these drugs only extend life by a few months on average,
Ticker (OTCBB) GNSZ
they constitute a huge market – for example, annual sales of Roche’s
Share Price (12/31/09) $1.95
Avastin are over $4B

Market Capitalization $30M

Lead drug is in Phase I clinical trial
• Impressive pre-clinical results with complete regression of tumors
Fiscal Year End Dec. 31 • Phase I clinical trial for the lead drug, G-202, is underway at Johns
Hopkins and Univ Wisconsin
Shares Outstanding
Basic 15.3 M Patented technology platform has additional applications
Fully Diluted 23.2 M • Technology platform supports the development of a suite of drugs
targeted at different cancers, as well as applications such as imaging
Insider Ownership 43% • Two other drug candidates are already in development

Corporate strategy to harvest significant value

• Identify a series of drugs based on the technology platform
Selected Balance Sheet Data
• Develop them through Phase I/II clinical trials
($ thousands) • Realize the significant value of these efforts after Phase I/II trials
through licensing/sales to big pharma without incurring the time, cost
Cash & Equivalents $2,742 and risk of building a pharmaceutical marketing and sales organization
Total Assets $2,909
Experienced and well-developed team driving the process
Total Liabilities $2,417
• Core team has extensive experience in successfully identifying and
Total S/H Equity $ 492 bringing oncology treatments to the clinic
9/30/2009

Business Risks and Forward-Looking Statements

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements set forth above that are not historical facts are forward-looking statements that involve risks and
uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors include, but are not limited to, the effect of political, economic, and market
conditions and geopolitical events, legislative and regulatory changes, the Company’s ability to expand its operations, the actions and initiatives of current and potential competitors, and other
factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. This Profile of GenSpera was developed by
the Company and is intended solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy the Company’s stock. This Profile is based upon
information available to the public, as well as other information from sources which management believes to be reliable, but is not guaranteed by GenSpera as being accurate nor does it purport to
be complete. Opinions expressed herein are those of management as of the date of publication and are subject to change without notice.